Aspira Women’s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford

Samples to be used in validating the Company’s EndoCheck^SM test in development for the diagnosis of endometriosis

AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company’s endometriosis blood test algorithms. Aspira expects to use the samples to support the launch of EndoCheck^SM, its first-generation blood test to aid in the diagnosis of endometriosis, by the end of 2023.

“We are excited to enter into this agreement with The University of Oxford. With their samples, we will be able to drive our EndoCheck validation process forward and bring this much needed test to market,” said Nicole Sandford, Chief Executive Officer of Aspira. “There are currently more than six million women suffering from endometriosis in the U.S., with many facing years of pain before getting a diagnosis. We intend to provide clinicians with a highly effective tool to assess the likelihood that a patient’s chronic pain is caused by endometriosis without an invasive procedure. I believe the availability of a simple blood test will support the development and adoption of new therapeutic solutions for this devastating disease, and help patients access treatments sooner than is possible today.”

Professor Christian Becker, from the Nuffield Department of Women’s and Reproductive Health, University of Oxford and Co-Director of the Oxford Endometriosis Care (EndoCaRe) Centre said, “An important step towards improving outcomes for women with endometriosis is faster, more reliable diagnosis. We are excited to support Aspira Women’s Health in developing a much-needed test for the identification of this debilitating disease.”

About EndoCheck^SM
EndoCheck is a non-invasive blood test in development to be used in conjunction with other non-surgical modalities to aid in the diagnosis of endometriosis and guide in the clinical care for patients with suspected endometriosis earlier in their prognosis journey. Current detection methods for endometriosis require surgery and a surgical biopsy diagnosis and/or visualization diagnosis. EndoCheck is intended to address this large patient population by using a non-invasive solution with comparable sensitivity and specificity when compared to invasive methods such as surgical biopsy and/or visualization.